



Prevalence of self-reported visual impairment in Canadians with and without diabetes: findings from population-based surveys from 1994 to 2014

Journal:	<i>CMAJ Open</i>
Manuscript ID	CMAJOpen-2022-0116
Manuscript Type:	Cross-sectional
Date Submitted by the Author:	20-May-2022
Complete List of Authors:	Im, James; University of Toronto Dalla Lana School of Public Health, Trope, Graham; University of Toronto, Department of Ophthalmology and Vision Sciences Buys, Yvonne; University of Toronto, Department of Ophthalmology and Vision Sciences Yan, Peng; University of Toronto, Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada Brent, Michael; University of Toronto, Department of Ophthalmology and Vision Sciences, Department of Medicine Liu, Sophia; Western University Schulich School of Medicine & Dentistry, Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada Jin, Yaping; University of Toronto, Department of Ophthalmology and Vision Sciences; University of Toronto Dalla Lana School of Public Health, Department of Public Health Sciences
Keywords:	Diabetes, Epidemiology, Public health
More Detailed Keywords:	visual impairment, prevalence, diabetes, population surveys, self-report
Abstract:	<p>Background: Visual impairment (VI) negatively impacts an individual's quality of life. Diabetes is a leading cause of VI. Approximately 1 in 11 Canadian adults are living with diabetes. We assessed trends in the prevalence of VI among Canadians with and without diabetes.</p> <p>Methods: Self-reported data from respondents aged 45+ in seven cycles of nationwide surveys (National Population Health Survey and Canadian Community Health Survey) from 1994/1995 to 2013/2014 were analyzed. The age- and sex-standardized prevalence of VI was calculated using the 2016 Canadian population as the standard. Comparisons by levels of education and income were assessed, utilising sex-standardised prevalence due to sparse data.</p> <p>Results: Among Canadians with diabetes, the age- and sex-standardized VI prevalence was 7.37% (95% confidence interval [CI] 5.31%-9.43%) in 1994/1997, decreasing to 3.03% (95% CI 2.48%-3.57%) in</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>2013/2014, giving a standardized prevalence ratio (SPR) of 0.41 (95% CI 0.30-0.56) comparing 2013/2014 to 1994/1997. Among Canadians without diabetes, VI prevalence decreased from 3.72% (95% CI 3.31%-4.14%) in 1994/1997 to 1.69% (95% CI 1.52%-1.87%) in 2013/2014, with an SPR of 0.45 (95% CI 0.40-0.52). Decreased sex-standardized VI prevalence was observed among Canadians with high and low levels of education and incomes in both those with and without diabetes.</p> <p>Interpretation: VI prevalence was roughly two times higher in those with vs without diabetes. From 1994 to 2014, VI prevalence decreased in those with and without diabetes irrespective of education and income levels. These results suggest effective collective efforts by eye care clinicians, other medical clinicians, researchers, the public, and government.</p>

SCHOLARONE™
Manuscripts

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	6,7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6,7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	8
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-11
Discussion			
Key results	18	Summarise key results with reference to study objectives	11,12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13,14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	11,12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3 Research Paper
4

5 **Title:** Prevalence of self-reported visual impairment in Canadians with and without diabetes:
6 findings from population-based surveys from 1994 to 2014
7
8

9
10 **Full Author Details:**

11 James H.B. Im, MPH¹
12 Graham E. Trope, MD²
13 Yvonne M. Buys, MD²
14 Peng Yan, MD^{2,3}
15 Michael H. Brent, MD²
16 Sophia Y. Liu, MD⁴
17 Ya-Ping Jin, MD^{1,2*}
18
19
20

21
22 **Author Affiliations:**

23 ¹Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
24 ²Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada
25 ³Kensington Vision and Research Centre, Toronto, Canada
26 ⁴Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University,
27 London, Canada
28

29
30 ***Corresponding Author:**

31 Ya-Ping Jin, MD, PhD
32 Department of Ophthalmology and Vision Sciences
33 University of Toronto
34 340 College Street, Suite 400
35 Toronto, Ontario, Canada
36 M5T 1S8
37 Telephone: 416-978-7938
38 E-mail: yaping.jin@utoronto.ca
39
40

41 **Acknowledgements:**

42 The authors acknowledge that the data used in this publication are from the National Population
43 Health Survey in 1994-1995, 1996-1997, 1998-1999, and the Canadian Community Health
44 Surveys in 2000-2001, 2008-2009, 2009-2010, 2013-2014. Both surveys were run by Statistics
45 Canada. The authors thank all participants of these surveys and the staff from Statistics Canada
46 who assisted in the survey data collection and management.
47
48

49 This research was supported by funds from the Canadian Research Data Centre Network
50 (CRDCN) from the Social Science and Humanities Research Council (SSHRC), the Canadian
51 Institute for Health Research (CIHR), the Canadian Foundation for Innovation (CFI), and Statistics
52 Canada.
53
54
55
56
57

1
2
3 Although the research and analysis are based on data from Statistics Canada, the opinions
4 expressed do not represent the views of Statistics Canada or the Canadian Research Data Centre
5 Network (CRDCN).
6

7
8 **Meeting Presentation:** The study abstract was presented at the Association for Research in Vision
9 & Ophthalmology (ARVO) Annual Meeting in May 2021 and the Canadian Ophthalmological
10 Society (COS) Annual Meeting in June 2021, both presented online due to the COVID-19
11 pandemic.
12

13 **Word Counts**

14 Abstract: 250
15 Manuscript text: 2440
16 Number of Tables: 2
17 Number of Figures: 3
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

Abstract

Background: Visual impairment (VI) negatively impacts an individual's quality of life. Diabetes is a leading cause of VI. Approximately 1 in 11 Canadian adults are living with diabetes. We assessed trends in the prevalence of VI among Canadians with and without diabetes.

Methods: Self-reported data from respondents aged 45+ in seven cycles of nationwide surveys (National Population Health Survey and Canadian Community Health Survey) from 1994/1995 to 2013/2014 were analyzed. The age- and sex-standardized prevalence of VI was calculated using the 2016 Canadian population as the standard. Comparisons by levels of education and income were assessed, utilising sex-standardised prevalence due to sparse data.

Results: Among Canadians with diabetes, the age- and sex-standardized VI prevalence was 7.37% (95% confidence interval [CI] 5.31%-9.43%) in 1994/1997, decreasing to 3.03% (95% CI 2.48%-3.57%) in 2013/2014, giving a standardized prevalence ratio (SPR) of 0.41 (95% CI 0.30-0.56) comparing 2013/2014 to 1994/1997. Among Canadians without diabetes, VI prevalence decreased from 3.72% (95% CI 3.31%-4.14%) in 1994/1997 to 1.69% (95% CI 1.52%-1.87%) in 2013/2014, with an SPR of 0.45 (95% CI 0.40-0.52). Decreased sex-standardized VI prevalence was observed among Canadians with high and low levels of education and incomes in both those with and without diabetes.

Interpretation: VI prevalence was roughly two times higher in those with vs without diabetes. From 1994 to 2014, VI prevalence decreased in those with and without diabetes irrespective of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

education and income levels. These results suggest effective collective efforts by eye care clinicians, other medical clinicians, researchers, the public, and government.

Trial registration: Not applicable

Key words: Visual impairment, prevalence, diabetes, population surveys, self-report

Confidential

1
2
3 Visual impairment (VI) is recognised as a major public health issue due to its significant impacts
4 on independence, risk of accidents/injuries, falls, depression, and quality of life.¹⁻⁴ Diabetes is a
5 leading cause of VI in developed countries, particularly in working-age individuals, owing to the
6 development of diabetic retinopathy and diabetic macular edema.⁵ In Canada the prevalence of
7 diabetes increased 37.3% between 2003/2004 and 2013/2014, with an annual increase rate of
8 1.2% since 2010.⁶ Approximately 3.2 million Canadians, or 1 in 11 adults aged 20+, were living
9 with diabetes in 2016/2017.⁷

10
11
12 Given the fast-rising prevalence of diabetes in recent decades, it is important to know whether
13 the prevalence of VI has also increased. This will help us understand the magnitude and burden
14 of VI, guide necessary health and social service planning, and aid in the development of
15 strategies and policies for VI prevention and management. We assessed time trends in VI
16 prevalence among Canadians with and without diabetes over the past two decades and
17 determined if the trends were similar amongst Canadians with different levels of education and
18 income.

19 20 21 **Methods**

22 *Setting and Study Design*

23 The study setting included the 10 provinces of Canada. The study design was repeated,
24 population-based, cross-sectional surveys conducted in 1994/1995, 1996/1997, 1998/1999,
25 2000/2001, 2008/2009, 2009/2010, and 2013/2014.

26 *Data Source and Participants*

1
2
3 Data analyzed were obtained from seven cycles of nationwide surveys: the 1994/1995, 1996/1997
4 and 1998/1999 cycles of the National Population Health Survey (NPHS) and the 2000/2001,
5
6
7 2008/2009 Healthy Aging, 2009/2010 and 2013/2014 cycles of the Canadian Community Health
8
9 Survey (CCHS).
10
11
12
13

14 The CCHS and NPHS are cross-sectional surveys with participants randomly selected across the
15 country by Statistics Canada. The surveys covered 98% of Canadians aged 12+ living in private
16 dwellings.^{8,9} Overall response rates ranged from 69.7% to 92.8% for the NPHS and 72.3% to
17
18 87.3% for the CCHS.^{8,10-15} Only respondents aged 45+ were included in the analysis since VI is an
19
20 age-related condition and the CCHS 2008/2009 Healthy Aging cycle only included individuals
21
22 aged 45+.¹⁶
23
24
25
26
27
28
29
30

31 *Outcome Measure*

32
33 The study outcome was self-reported VI. This information was obtained from the survey
34
35 questions:
36
37

- 38 *1. Are you usually able to see well enough to read ordinary newsprint without glasses or*
39 *contact lenses?*
- 40 *2. Are you usually able to see well enough to read ordinary newsprint with glasses or*
41 *contact lenses?*
- 42 *3. Are you able to see at all?*
- 43 *4. Are you able to see well enough to recognize a friend on the other side of the street*
44 *without glasses or contact lenses?*
- 45 *5. Are you usually able to see well enough to recognize a friend on the other side of the*
46 *street with glasses or contact lenses?*
47
48
49
50
51
52
53
54
55
56
57

1
2
3 In this analysis, respondents who provided a negative response to questions 2, 3, or 5 were
4 considered as having self-reported VI. Respondents with a positive answer to the above
5 questions were categorized as not having self-reported VI.
6
7
8
9
10

11 *Diabetes Measure*

12
13
14 Participants who self-reported that they had diabetes diagnosed by a health professional were
15 considered as having diabetes. Conversely, those who responded as not having diabetes diagnosed
16 by a health professional were deemed as not having diabetes.
17
18
19
20
21

22 *Other Measures*

23
24
25 Participant age and sex was self-reported. Information on the highest level of education attained
26 by participants was obtained through a series of questions and was categorized by Statistics Canada
27 into four levels: “Less than secondary school graduation”, “Secondary school graduation, no post-
28 secondary”, “Some post-secondary education”, and “Post-secondary certificate/diploma or
29 university degree”.¹⁷ In this analysis, we further consolidated participants into low (less than
30 secondary school graduation or secondary school graduation) and high (some post-secondary
31 education or post-secondary certificate/diploma or university degree) levels to avoid sparse data.
32
33
34 Similarly, data on total household income was collected through a series of questions by Statistics
35 Canada, which were grouped into low (below middle) and mid/high (middle or higher) levels of
36 household income for each survey (See details in Table 1 footnote).
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 *Statistical Analyses*

1
2
3 The prevalence of VI was calculated as the proportion of individuals with VI among all
4 respondents. Prevalence estimates were stratified by diabetes status as well as level of education
5 and household income. Survey weights provided by Statistics Canada were used in all analyses to
6 account for sample selection, complex survey design, and adjust for seasonal effects, post-
7 stratification, non-response and calibration.¹⁸ Weighted data are more representative of the
8 surveyed population and are required by Statistics Canada when reporting population estimates.¹⁸
9 Weighted prevalence estimates and 95% confidence intervals (CIs) were directly age- and sex-
10 standardized to the 2016 Canadian census to allow for valid comparisons.¹⁹ For analyses stratified
11 by levels of education and income, only sex-standardized prevalence was calculated due to small
12 sample sizes when stratifying by both age and sex. The standard errors and associated 95% CIs of
13 prevalence estimates were calculated using the bootstrap weights provided by Statistics Canada.
14 Due to small cell sizes, the 1994/1995 and 1996/1997 cycles of the NPHS and the 1998/1999 and
15 2000/2001 cycles of the NPHS and CCHS were combined for calculating overall prevalence
16 estimates and education-stratified estimates.²⁰ For similar reasons, the 1998/1999 cycle of the
17 NPHS was combined with the 2000/2001 cycle of the CCHS for calculating income-stratified
18 estimates. Standardized prevalence ratios (SPR) and associated 95% CIs were calculated to
19 compare the prevalence of VI in 2013/2014 versus 1994/1997.²¹ Additive and multiplicative
20 interaction for education-diabetes and income-diabetes were assessed.²² Participants who
21 answered “Don’t know” or refused to answer the relevant questions were treated as missing values
22 and were excluded from the analyses. All statistical analyses were conducted using SAS 9.4 (SAS
23 Institute, Inc., Cary, NC).

24 *Ethics Approval*

1
2
3 Informed consent was obtained by Statistics Canada from all survey participants. This study was
4
5 approved by the University of Toronto Research Ethics Board.
6
7
8
9

10 **Results**

11 *Participant Characteristics*

12
13
14 The unweighted number of participants who had a valid answer to VI ranged from 6,930 in
15
16 1998/1999 to 75,808 in 2013/2014. For diabetes, this number ranged from 6,947 in 1998/1999 to
17
18 77,032 in 2013/2014. Unweighted missing values were 17-1,224 (0.00%-0.02%) for VI and 1-
19
20 127 (0.00%-0.00%) for diabetes.
21
22
23
24
25

26 The characteristics of participants with and without diabetes are shown in **Table 1**. The weighted
27
28 number of Canadians with diabetes aged 45+ increased from 607,100 in 1994/1995 to 1,772,200
29
30 in 2013/2014. Among Canadians with diabetes, the weighted number of individuals with VI
31
32 decreased from 57,200 in 1994/1995 to 53,900 in 2013/2014. Among those without diabetes, the
33
34 number of individuals with VI decreased from 344,400 in 1994/1995 to 205,900 in 2013/2014.
35
36 Missing values for included variables ranged from 0% for age and sex to 18.9% for income.
37
38
39
40
41

42 *Overall Trends in the Prevalence of VI*

43
44 The trend in the age- and sex-standardized VI prevalence among people with and without
45
46 diabetes is shown in Figure 1. In all survey years, the prevalence of VI was about two times
47
48 higher among Canadians with diabetes than those without. A consistently decreasing VI
49
50 prevalence was observed among both with and without diabetes groups. Among those with
51
52 diabetes, the prevalence of VI decreased from 7.37% (95% CI 5.31%-9.43%) in 1994/1997 to
53
54
55
56
57
58
59
60

1
2
3 3.02% (95% CI 2.48%-3.57%) in 2013-2014, giving an SPR of 0.41 (95% CI 0.30-0.56) for
4
5 2013/2014 versus 1994/1997. Among those without diabetes, the prevalence of VI decreased
6
7 from 3.72% (95% CI 3.31%-4.14%) in 1994-1997 to 1.69% (95% CI 1.52%-1.87%) in 2013-
8
9 2014, with an SPR of 0.45 (95% CI 0.40-0.52) for 2013/2014 versus 1994/1997.
10
11
12
13

14 *Trends in the Prevalence of VI Stratified by Levels of Education and Diabetes Status*

15
16
17 Figure 2 shows a decreasing prevalence of VI in all subgroups stratified by level of education
18
19 and diabetes status from 1994 to 2014. In the low-education stratum, the sex-standardized
20
21 prevalence of VI decreased from 9.96% (95% CI 6.91%-13.02%) in 1994-1997 to 3.57% (95%
22
23 CI 2.84%-4.29%) in 2013-2014 for those with diabetes, and from 4.16% (95% CI 3.52%-4.79%)
24
25 in 1994-1997 to 2.18% (95% CI 1.87%-2.48%) in 2013-2014 for those without diabetes. In the
26
27 high-education stratum, the VI prevalence similarly decreased from 6.04% (95% CI 2.20%-
28
29 9.88%) in 1994-1997 to 3.06% (95% CI 2.21%-3.91%) in 2013/2014 for those with diabetes, and
30
31 from 2.68% (95% CI 2.19%-3.17%) in 1994/1997 to 1.21% (95% CI 1.01%-1.41%) in 2013-
32
33 2014 for those without diabetes.
34
35
36
37
38
39

40
41 Figure 2 also shows that the sex-standardized VI prevalence was highest in Canadians with low
42
43 levels of education and diabetes, and lowest in those with high levels of education and no
44
45 diabetes in all survey years, except for 1998/2001. Evaluations of interactions regarding the joint
46
47 presence of low levels of education and having diabetes on the prevalence of VI are shown in
48
49 Table 2 (upper part). In 2013-2014, the observed SPR for joint presence of low level of
50
51 education and diabetes was smaller than the expected joint SPR from both the additive (2.36 vs
52
53 2.82) and multiplicative model (2.95 vs 4.56), indicating the presence of negative additive and
54
55
56
57
58
59
60

1
2
3 negative multiplicative interaction. Thus, interventions for VI tailored specifically to those with
4 low levels of education and diabetes might not have a larger effect.
5
6
7
8
9

10 *Trends in Prevalence of VI Stratified by Levels of Household Income and Diabetes Status*

11 Similar to the results grouped by level of education and diabetes status, a decreased VI
12 prevalence over time was observed after stratification by household income level and diabetes
13 status (Figure 3). The highest sex-standardized VI prevalence was found in Canadians with low
14 levels of household income and diabetes, and the lowest in those with high levels of income and
15 no diabetes in all survey years, except for 1998/2001. Evaluation of the interaction between the
16 joint presence of low level of household income and diabetes on the prevalence of VI are shown
17 in Table 2 (lower part). In 2013/2014, there was evidence of positive additive interaction
18 (observed SPR of 3.39 vs. expected SPR of 2.86), suggesting VI interventions targeting those
19 with low levels of household income and diabetes may likely yield a benefit larger than expected
20 based on the additive model.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Interpretation**

41 This study assessed VI trends amongst Canadians with and without diabetes over two decades.
42 We report that while the number of Canadians aged 45+ with diabetes nearly tripled from
43 1994/1995 (607,100) to 2013/2014 (1,772,200), the number of people with VI amongst those
44 with diabetes decreased (57,200 in 1994/1995 to 53,900 in 2013/2014). Among both people with
45 and without diabetes, the age- and sex-adjusted VI prevalence decreased by more than half, with
46 an SPR of 0.41 for those with diabetes and 0.45 for those without diabetes. Sex-adjusted analyses
47 after stratification by education and income levels also showed a decreasing trend from 1994 to
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 2014. Furthermore, we report the prevalence of VI was about two times higher in Canadians with
4
5 diabetes than those without in all survey years. The highest prevalence of VI was found in
6
7 Canadians with diabetes and low levels of education or income, and the lowest amongst those
8
9 without diabetes and with mid/high levels of education or income. In 2013/2014, a positive
10
11 additive interaction between diabetes and low levels of household income was noted. Thus, VI
12
13 interventions should be targeted at those with diabetes and low levels of household income.
14
15
16
17
18

19 Our finding of decreased prevalence of VI from 1994 to 2014 complements reports from other
20
21 countries regarding VI.^{23,24} In Europe, a meta-analysis by Delcourt *et al.* on the age-adjusted
22
23 prevalence of VI and blindness in individuals aged 55+ reported that VI prevalence decreased
24
25 from 2.22% for the period of 1991-2006 to 0.92% for the period of 2007-2012.²³ In another
26
27 meta-analysis, Flaxman *et al.* similarly reported that the age-adjusted prevalence of VI in people
28
29 aged 50+ decreased from 1990 to 2015 globally.²⁴ However, these reports did not distinguish
30
31 between people with and without diabetes, and used pooled data from different countries with
32
33 different healthcare systems. Using data from Canada, which has universal healthcare, we report
34
35 that VI prevalence decreased in people with and without diabetes from 1994 to 2014, irrespective
36
37 of their level of education and income. We believe these results likely reflect the collective
38
39 efforts by eye care clinicians, other medical clinicians, researchers, the public, and government
40
41 to prevent vision loss.
42
43
44
45
46
47
48

49 Our results also agree with studies that have reported a significantly higher prevalence of VI in
50
51 people with diabetes than those without.²⁵⁻²⁷ We report that despite the prevalence of VI
52
53 continuously decreasing over time, the prevalence of VI in the most recent survey year
54
55
56
57

1
2
3 2013/2014 was still significantly higher in Canadians with diabetes vs. those without (3.03% vs.
4
5 1.69%). This demonstrates that diabetes is still a major cause of VI in Canada. Preventing and
6
7 treating diabetes and diabetic retinopathy needs to remain a priority in Canada. Amongst those
8
9 with diabetes, early detection, good blood sugar control, and treatment of VI through screening
10
11 programs and diabetic eye exams are essential to protect vision, since vision loss from diabetic
12
13 retinopathy and diabetic macular edema can be irreversible. Low income earners with diabetes
14
15 are less likely to utilise recommended diabetic eye examinations despite universal health
16
17 coverage.²⁸⁻³⁰ Reported barriers include limited accessibility to eye care clinicians due to
18
19 geographic challenges and lack of knowledge about eye screening services.³¹⁻³³ Programs to
20
21 increase the uptake of diabetic eye exams, particularly those aimed at poor neighborhoods,
22
23 including diabetic eye screening services in primary care settings (e.g. the tele-retinal screening
24
25 program in Toronto) are effective and highly recommended.³⁴
26
27
28
29
30
31
32

33 *Limitations*

34
35 This study has several limitations. First, information on VI was self-reported, not clinically
36
37 confirmed, and in some cases may be correctable through corrective eyewear and surgery.
38
39 However, regardless of whether the reported VI is correctable, people continue to live with this
40
41 condition, which reflects real-life vision challenges faced by many individuals. Second, although
42
43 self-reported diabetes has an excellent specificity (87.8%-98.6%), it has only a moderate
44
45 sensitivity (41.5%-70.4%).³⁵⁻³⁷ Moderate sensitivity may lead to misclassification of some
46
47 individuals with diabetes as not having diabetes, resulting in an over-estimation of VI
48
49 prevalence. However, we are not aware of evidence that suggests the validity of self-reported
50
51 diabetes changes with time. Therefore, we do not think misclassification of self-reported diabetes
52
53
54
55
56
57
58
59
60

1
2
3 would impact the decreasing trend reported. Third, the most recent data available on VI is the
4
5 CCHS 2013/2014 due to survey content changes by Statistics Canada. Although VI data from
6
7 more recent years are desirable, our results provide a 20-year historic picture for use in future
8
9 comparisons.
10

11 *Conclusion*

12
13
14
15
16
17 In conclusion, the prevalence of VI in Canada is higher in people with diabetes versus those
18
19 without. Overall, the prevalence of VI in Canada decreased from 1994 to 2014. This trend was
20
21 observed in all subgroups stratified by diabetes status and level of education and income.
22
23
24 Statistics Canada should be encouraged to keep VI questions in future surveys to allow for
25
26 ongoing analysis of the vision health of Canadians. To reduce VI burden in Canada, efforts and
27
28 research should continue to focus on diabetes education, treatment and prevention as well as
29
30 improving access to diabetic eye exams particularly for those from lower-income households.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgments:** None.
4
5

6 **Funding:** This research was supported by funds to the Canadian Research Data Centre Network
7 from the Social Sciences and Humanities Research Council, the Canadian Institutes of Health
8 Research, the Canadian Foundation for Innovation and Statistics Canada.
9

10
11 **Author Contributions:** James H.B. Im led data analyses, drafted and revised the manuscript,
12 and prepared tables and figures. Ya-Ping Jin, Graham E. Trope, Yvonne M. Buys, Peng Yan,
13 Michael H. Brent, and Sophia Y. Liu conceived the study. Ya-Ping Jin designed the study,
14 acquired data access, resolved analysis related issues and led the manuscript revision. All authors
15 contributed to data interpretation, revised the manuscript critically for important intellectual
16 content, gave final approval of the version to be published and agreed to act as guarantors of this
17 work and take responsibility for the contents of the article.
18
19
20

21
22 **Data Sharing:** Access to this third-party data set is through the Statistics Canada Research Data
23 Centres (RDCs) Program, which has centres at universities across Canada. Research Data
24 Centres are operated under the provisions of the Canadian Statistics Act, which states that
25 persons retained under contract to perform special services under this act are deemed to be
26 persons employed under this act while performing those services, in accordance with all the
27 confidentiality rules. Anyone may apply to access the data by submitting a research proposal that
28 justifies the need for access to confidential microdata to address a question that has relevance for
29 the Canadian population. On approval, researchers undergo a deeming process, and a contract is
30 granted. Thus, access to the data is granted on a need-to-know basis. For those interested in
31 obtaining access to these data sets, detailed contact information and application processes to gain
32 access and guidelines to use RDC data can be found at [https://](https://www.statcan.gc.ca/eng/rdc/process)
33 www.statcan.gc.ca/eng/rdc/process.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Hong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ. Visual Impairment and the Incidence of Falls and Fractures Among Older People: Longitudinal Findings From the Blue Mountains Eye Study. *Invest Ophthalmol Vis Sci.* 2014;55(11):7589-93.
2. Yip JLY, Khawaja AP, Broadway D, Luben R, Hayat S, Dalzell N, et al. Visual acuity, self-reported vision and falls in the EPIC-Norfolk Eye study. *Br J Ophthalmol.* 2014;98(3):377-82.
3. Jin Y-P, Wong DT. Self-reported visual impairment in elderly Canadians and its impact on healthy living. *Can J Ophthalmol.* 2008;43(4):407-13.
4. Crews JE, Chou CF, Zack MM, Zhang X, Bullard KM, Morse AR, et al. The Association of Health-Related Quality of Life with Severity of Visual Impairment among People Aged 40–64 Years: Findings from the 2006–2010 Behavioral Risk Factor Surveillance System. *Ophthalmic Epidemiol.* 2016;23(3):145-53.
5. Diabetes Canada Clinical Practice Guidelines Expert Committee; Altomare F, Kherani A, Lovshin J. Retinopathy. *Can J Diabetes.* 2018;42 Suppl 1:S210-S216.
6. Government of Canada. Diabetes in Canada [Internet]. Ottawa (ON): Government of Canada; [updated 2020 Aug 17; cited 2022 Mar 26]. Available from: <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/diabetes-canada-highlights-chronic-disease-surveillance-system.html>.
7. LeBlanc AG, Jun Gao Y, McRae L, Pelletier C. At-a-glance - Twenty years of diabetes surveillance using the Canadian Chronic Disease Surveillance System. *Health Promot Chronic Dis Prev Can.* 2019;39(11):306-9.
8. Statistics Canada. National Population Health Survey: Household Component, Cross-sectional (NPHS). Detailed Information for 1998-1999 [Internet]. Ottawa (ON): Statistics Canada; [updated 2007 Oct 24; cited 2021 Jan 10]. Available from: <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3236>.
9. Statistics Canada. Canadian Community Health Survey - Annual Component (CCHS) [Internet]. Ottawa (ON): Statistics Canada; [updated 2021 Dec 29; cited 2021 Jan 10]. Available from: <https://www.statcan.gc.ca/en/survey/household/3226>.
10. Statistics Canada. National Population Health Survey: Household Component, Cross-sectional (NPHS). Detailed Information for 1994-1995 [Internet]. Ottawa (ON): Statistics Canada; [updated 2007 Oct 24; cited 2021 Jan 10]. Available from: <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=3732>.
11. Statistics Canada. National Population Health Survey: Household Component, Cross-sectional (NPHS). Detailed Information for 1996-1997 [Internet]. Ottawa (ON): Statistics Canada; [updated 2007 Oct 24; cited 2021 Jan 10]. Available from: <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=4520>.
12. Statistics Canada. CCHS Cycle 1.1 (2000-2001), Public Use Microdata File Documentation. Ottawa (ON): Statistics Canada.
13. Statistics Canada. Canadian Community Health Survey (CCHS) – Healthy Aging User Guide. Ottawa (ON): Statistics Canada.
14. Statistics Canada. 2010 and 2009-2010 CCHS Microdata File User Guide. Ottawa (ON): Statistics Canada.

15. Statistics Canada. 2014 and 2013-2014 CCHS Microdata File User Guide. Ottawa (ON): Statistics Canada.
16. Statistics Canada. Canadian Community Health Survey - Healthy Aging (CCHS) [Internet]. Ottawa (ON): Statistics Canada; [updated 2008 Nov 27; cited 2021 Jan 10]. Available from: <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5146>.
17. Statistics Canada. Canadian Community Health Survey (CCHS) Derived Variable (DV) Specifications. Ottawa (ON): Statistics Canada; [2011 Jun; cited 2021 Jan 10]. Available from: http://www23.statcan.gc.ca/imdb-bmdi/pub/document/3226_D5_T9_V1-eng.pdf.
18. Statistics Canada. Canadian Community Health Survey (CCHS) Household Weights Documentation. Ottawa (ON): Statistics Canada; [2010 May; cited 2021 Jan 10]. Available from: https://www23.statcan.gc.ca/imdb-bmdi/pub/document/3226_D57_T9_V1-eng.htm.
19. Naing NN. Easy way to learn standardization : direct and indirect methods. *Malays J Med Sci.* 2000;7(1):10-5.
20. Thomas S, Wannell B. Combining cycles of the Canadian Community Health Survey. *Health Rep.* 2009;20(1):53-8.
21. Boyle P, Parkin DM. Cancer registration: principles and methods. *Statistical methods for registries.* IARC Sci Publ. 1991;95:126-58.
22. Szklo, & Nieto, F. J. (2019). *Epidemiology : beyond the basics* (Fourth edition.). Jones & Bartlett Learning.
23. Delcourt C, Le Goff M, von Hanno T, Mirshahi A, Khawaja AP, Verhoeven VJM, et al. The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans: A Meta-analysis of Published and Unpublished Data. *Ophthalmology.* 2018;125(8):1149-59.
24. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health.* 2017;5(12):e1221-e1234.
25. Norris KL, Beckles GL, Chou CF, Zhang X, Saaddine J. Association of Socioeconomic Status with Eye Health Among Women With and Without Diabetes. *J Womens Health (Larchmt).* 2016;25(3):321-6.
26. Yan X, Chen L, Yan H. Socio-economic status, visual impairment and the mediating role of lifestyles in developed rural areas of China. *PLoS One.* 2019;14(4):e0215329.
27. Perruccio AV, Badley EM, Trope GE. A Canadian population-based study of vision problems: Assessing the significance of socioeconomic status. *Can J Ophthalmol.* 2010;45(5):477-83.
28. Pampel FC, Krueger PM, Denney JT. Socioeconomic Disparities in Health Behaviors. *Annu Rev Sociol.* 2010 Aug;36:349-70.
29. Mcmaughan DJ, Oloruntopa O, Smith ML. Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging. *Front Public Health.* 2020;8:231.
30. Ballios BG, Park T, Chaudhary V, Hurley B, Kosar S, Sheidow T, et al. Identifying gaps in patient access to diabetic screening eye examinations in Ontario: a provincially representative cross-sectional study. *Can J Ophthalmol.* 2021;56(4):223-30.
31. Egunsola O, Dowsett LE, Diaz R, Brent MH, Rac V, Clement FM. Diabetic Retinopathy Screening: A Systematic Review of Qualitative Literature. *Can J Diabetes.* 2021;45(8):725-33.

- 1
2
3 32. Leese GP, Boyle P, Feng Z, Emslie-Smith A, Ellis JD. Screening uptake in a well-established
4 diabetic retinopathy screening program: the role of geographical access and deprivation.
5 *Diabetes Care*. 2008;31(11):2131-5.
6
7 33. Maberley DAL, Koushik A, Cruess AF. Factors associated with missed eye examinations in
8 a cohort with diabetes. *Can J Public Health*. 2002;93(3):229–32.
9
10 34. Felfeli T, Alon R, Merritt R, Brent MH. Toronto tele-retinal screening program for detection
11 of diabetic retinopathy and macular edema. *Can J Ophthalmol*. 2019;54(2):203-11.
12
13 35. Goto A, Morita A, Goto M, Sasaki S, Miyachi M, Aiba M, et al. Validity of diabetes self-
14 reports in the Saku diabetes study. *J Epidemiol*. 2013;23(4):295-300.
15
16 36. Yuan X, Liu T, Wu L, Zou Z-Y, Li C. Validity of self-reported diabetes among middle-aged
17 and older Chinese adults: the China Health and Retirement Longitudinal Study. *BMJ Open*.
18 2015;5(4):e006633.
19
20 37. de Menezes TN, Oliveira ECT. Validity and concordance of self-reported diabetes mellitus
21 by the elderly. *Cien Saude Colet*. 2019;24(1):27-34.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure Legend**

4 **Figure 1.** The age- and sex-standardized prevalence of visual impairment in the 10 Canadian
5 provinces from 1994 to 2014

6
7 **Figure 2.** The sex-standardized prevalence of visual impairment in the 10 Canadian provinces
8 stratified by education levels from 1994 to 2014. **A.** Low level of education. **B.** Mid/high level of
9 education

10 **Figure 3.** The sex-standardized prevalence of visual impairment in the 10 Canadian provinces
11 stratified by household income levels from 1994 to 2014. **A.** Low level of household income. **B.**
12 Mid/high level of household income
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 1. Weighted characteristics of participants aged 45+ in the National Population Health Survey (NPHS) and the Canadian Community Health Survey (CCHS) with and without diabetes, 1994-2014

People with Diabetes														
NPHS and CCHS Cycles														
	1994/1995 (unweighted n=525)		1996/1997 (unweighted n=2,322)		1998/1999 (unweighted n=537)		2000/2001 (unweighted n=5,431)		2008/2009 (unweighted n=4,384)		2009/2010 (unweighted n=8,866)		2013/2014 (unweighted n=10,566)	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	(100's)		(100's)		(100's)		(100's)		(100's)		(100's)		(100's)	
Age														
45-64	2438	40.2	3109	46.5	3231	44.7	4356	48.5	7986	51.5	7715	49.2	8478	47.8
65-74	2272	37.4	2064	30.9	2177	30.1	2767	30.8	4239	27.3	4347	27.7	5400	30.5
75+	1361	22.4	1511	22.6	1824	25.2	1855	20.7	3280	21.2	3615	23.1	3845	21.7
45+	6071	100.0	6683	100.0	7232	100.0	8978	100.0	15505	100.0	15677	100.0	17722	100.0
Sex														
Male	3102	51.1	3655	54.7	3868	53.5	4752	52.9	8198	52.9	8881	56.6	9827	55.5
Female	2969	48.9	3027	45.3	3365	46.5	4226	47.1	7307	47.1	6796	43.4	7895	44.5
Annual Household Income*														
Low Income	2044	33.7	2952	44.2	3557	49.2	3638	40.5	5762	37.2	5516	35.2	7230	40.8
Mid/High Income	3713	61.2	2633	39.4	3177	43.9	4295	47.8	7026	45.3	7205	46.0	10488	59.2
Missing	314	5.2	1097	16.4	498	6.9	1045	11.6	2717	17.5	2956	18.9	4	0.0
Highest Level of Education Achieved														
No Post-Secondary Education	3896	64.2	4159	62.2	4422	61.1	5522	61.5	8260	53.3	7321	46.7	8660	48.9
Post-Secondary Education or higher	2055	33.8	2472	37.0	2773	38.3	3341	37.2	6941	44.8	7768	49.6	8557	48.3
Missing	120	2.0	52	0.8	37	0.5	115	1.3	304	2.0	587	3.7	506	2.9
Visual Impairment														
Yes	572	9.4	473	7.1	525	7.3	521	5.8	567	3.7	470	3.0	539	3.0

No	5431	89.4	6188	92.6	6705	92.7	8420	93.8	14819	95.6	15060	96.1	16943	95.6
Missing	69	1.1	22	0.3	3	0.0	36	0.4	119	0.8	147	0.9	241	1.4
People without Diabetes														
NPHS and CCHS Cycles														
	1994/1995 (unweighted n=7,059)		1996/1997 (unweighted n=30,039)		1998/1999 (unweighted n=6,410)		2000/2001 (unweighted n=55,156)		2008/2009 (unweighted n=26,468)		2009/2010 (unweighted n=59,771)		2013/2014 (unweighted n=66,466)	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	(100's)		(100's)		(100's)		(100's)		(100's)		(100's)		(100's)	
Age														
40-64	57140	66.5	60218	66.3	63541	67.3	68222	68.2	84602	70.1	86033	70.2	89101	67.6
65-74	18289	21.3	18888	20.8	17747	18.8	18762	18.8	19833	16.4	21020	17.2	25719	19.5
75+	10536	12.3	11685	12.9	13059	13.8	13003	13.0	16314	13.5	15461	12.6	16902	12.8
45+	85964	100.0	90791	100.0	94346	100.0	99987	100.0	120749	100.0	122515	100.0	131722	100.0
Sex														
Male	40519	47.1	42634	47.0	44375	47.0	47062	47.1	57284	47.4	57639	47.0	62392	47.4
Female	45445	52.9	48157	53.0	49972	53.0	52925	52.9	63465	52.6	64876	53.0	69330	52.6
Annual Household Income*														
Low Income	21201	24.7	29913	32.9	31363	33.2	26440	26.4	28414	23.5	28848	23.5	36393	27.6
Mid/High Income	60114	69.9	44667	49.2	55883	59.2	61970	62.0	71573	59.3	72301	59.0	95299	72.3
Missing	4649	5.4	16211	17.9	7100	7.5	11578	11.6	20762	17.2	21365	17.4	30	0.0
Highest Level of Education Achieved														
No Post-Secondary Education	44692	52.0	45833	50.5	44915	47.6	49601	49.6	48754	40.4	43195	35.3	48942	37.2
Post-Secondary Education	41105	47.8	43878	48.3	49385	52.3	49325	49.3	70509	58.4	75587	61.7	80189	60.9
Missing	167	0.2	1080	1.2	46	0.0	1062	1.1	1486	1.2	3732	3.0	2591	2.0
Visual Impairment														
Yes	3444	4.0	2702	3.0	3452	3.7	2252	2.3	1948	1.6	1961	1.6	2059	1.6
No	81801	95.2	87689	96.6	90717	96.2	97333	97.3	118297	98.0	119689	97.7	128280	97.4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Missing	720	0.8	400	0.4	177	0.2	403	0.4	504	0.4	865	0.7	1384	1.1
---------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	-----

* Low income: an annual household income of \$0-\$19,999 for the 1994/1995 NPHS cycle, \$0-\$29,999 for the 1996/1997 and 1998/1999 NPHS cycles as well as the 2000/2001 CCHS cycle, and \$0-\$39,999 for the 2008/2009, 2009/2010 and 2013/2014 CCHS cycles. In 2013/2014, missing income data were imputed by Statistics Canada.¹⁸

Confidential

Table 2. The observed (95% CI) and expected joint standardized prevalence ratio (SPR) from the additive and multiplicative models in assessing the joint effects of diabetes and level of education (upper part) and level of household income (lower part) on the prevalence of visual impairment (VI)

		Observed joint SPR	Expected joint SPR	Suggested presence of interaction
Education+Diabetes+ vs Education-Diabetes^{-a}				
1994/1997	Additive Model	7.28 (7.25-7.31)	4.84	Positive additive
	Multiplicative Model	3.72 (2.39-5.79)	3.50	
1998/2001	Additive Model	4.22 (4.20-4.24)	5.94	Negative additive and negative multiplicative
	Multiplicative Model	2.80 (2.11-3.71)	4.57	
2008/2009	Additive Model	2.38 (2.37-2.39)	2.75	Negative additive and negative multiplicative
	Multiplicative Model	3.05 (2.45-3.80)	4.72	
2009/2010	Additive Model	2.67 (2.66-2.68)	1.55	Positive additive
	Multiplicative Model	3.10 (2.49-3.87)	2.59	
2013/2014	Additive Model	2.36 (2.35-2.37)	2.82	Negative additive and negative multiplicative
	Multiplicative Model	2.95 (2.42-3.60)	4.56	
Income+Diabetes+ vs Income-Diabetes^{-b}				
1994/1995	Additive Model	9.48 (9.41-9.55)	8.14	Positive additive
	Multiplicative Model	3.72 (1.94-7.14)	4.73	
1996/1997	Additive Model	5.03 (5.00-5.06)	7.76	Negative additive and negative multiplicative
	Multiplicative Model	3.32 (2.18-5.05)	6.96	
1998/2001	Additive Model	6.23 (6.21-6.25)	6.01	Positive additive and negative multiplicative
	Multiplicative Model	4.08 (2.83-5.89)	6.19	
2008/2009	Additive Model	2.93 (2.91-2.94)	3.86	Negative additive and negative multiplicative
	Multiplicative Model	4.05 (3.09-5.31)	9.06	
2009/2010	Additive Model	3.01 (3.00-3.02)	2.09	Positive additive

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Multiplicative Model	3.57 (2.84-4.49)	3.57	
2013/2014	Additive Model	3.39 (3.38-3.40)	2.86	Positive additive
	Multiplicative Model	3.90 (3.06-4.97)	4.91	

^aEducation-Diabetes-: Mid/high level of education without diabetes; Education+Diabetes+: Low level of education with diabetes

^bIncome-Diabetes-: Mid/high level of household income without diabetes; Income+Diabetes+: Low level of household income with diabetes

Confidential




Figure 1. The age- and sex-standardized prevalence of visual impairment in the 10 Canadian provinces from 1994 to 2014

165x106mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. The sex-standardized prevalence of visual impairment in the 10 Canadian provinces stratified by education levels from 1994 to 2014. A. Low level of education. B. Mid/high level of education

417x447mm (38 x 38 DPI)




Figure 3. The sex-standardized prevalence of visual impairment in the 10 Canadian provinces stratified by household income levels from 1994 to 2014. A. Low level of household income. B. Mid/high level of household income

408x453mm (38 x 38 DPI)